Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 17, 2004. The report details a share repurchase transaction executed on September 16, 2004, and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks and treasury holdings.
- Shares Repurchased: 425,000 Ordinary shares.
- Repurchase Price: 1,175.1542 pence per share.
- Total Treasury Shares: 44,598,000 shares held following the transaction.
- Shares in Issue: 5,890,149,348 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through a buyback authorized at the Annual General Meeting on May 17, 2004. Additionally, the GlaxoSmithKline Employee Trust transferred 9,217 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on September 15, 2004.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 425,000 share repurchase against the stated price of 1,175.1542 pence.
- Confirm the updated total share count (5,890,149,348) in subsequent filings to ensure accuracy of the treasury calculation.
- Review the impact of the 9,217 share transfer from the GSK Trust on the specific directors mentioned (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe).